Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular OutcoMes for People Using Anticoagulation StrategieS (COMPASS) Trial

Conclusion COMPASS will provide information on the efficacy and safety of rivaroxaban, alone or in combination with aspirin, in the long-term management of patients with stable CAD or PAD, and on the efficacy and safety of pantoprazole in preventing upper GI complications in patients receiving antithrombotic therapy. Teaser COMPASS is a global randomized controlled trial comparing rivaroxaban 2.5mg twice-daily plus aspirin 100mg once-daily, rivaroxaban 5mg twice-daily, and aspirin 100mg once-daily for prevention of myocardial infarction, stroke, or cardiovascular death in patients with stable coronary or peripheral artery disease. Of 27,395 participants randomized between March 2013 and May 2016, 17,603 participants not already receiving a proton pump inhibitor were also randomized to receive pantoprazole 40mg once-daily or placebo for prevention of upper gastrointestinal complications.
Source: Canadian Journal of Cardiology - Category: Cardiology Source Type: research